JP2001095563A - イオン交換クロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法 - Google Patents

イオン交換クロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法

Info

Publication number
JP2001095563A
JP2001095563A JP2000236804A JP2000236804A JP2001095563A JP 2001095563 A JP2001095563 A JP 2001095563A JP 2000236804 A JP2000236804 A JP 2000236804A JP 2000236804 A JP2000236804 A JP 2000236804A JP 2001095563 A JP2001095563 A JP 2001095563A
Authority
JP
Japan
Prior art keywords
proenzyme
protease
protein
blood coagulation
factor vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000236804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001095563A5 (https=
Inventor
Juergen Dr Roemisch
イュルゲン・レーミシュ
Annette Feussner
アネッテ・フォイスナー
Hans-Arnold Stoehr
ハンス−アルノルト・シュテール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
Aventis Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring GmbH filed Critical Aventis Behring GmbH
Publication of JP2001095563A publication Critical patent/JP2001095563A/ja
Publication of JP2001095563A5 publication Critical patent/JP2001095563A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2000236804A 1999-08-06 2000-08-04 イオン交換クロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法 Pending JP2001095563A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937219A DE19937219A1 (de) 1999-08-06 1999-08-06 Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
DE19937219:5 1999-08-06

Publications (2)

Publication Number Publication Date
JP2001095563A true JP2001095563A (ja) 2001-04-10
JP2001095563A5 JP2001095563A5 (https=) 2007-06-07

Family

ID=7917489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000236804A Pending JP2001095563A (ja) 1999-08-06 2000-08-04 イオン交換クロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法

Country Status (8)

Country Link
US (2) US6677440B1 (https=)
EP (1) EP1074616B1 (https=)
JP (1) JP2001095563A (https=)
KR (1) KR20010049988A (https=)
AT (1) ATE386798T1 (https=)
CA (1) CA2315306A1 (https=)
DE (2) DE19937219A1 (https=)
ES (1) ES2298110T3 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009002709A (ja) * 2007-06-19 2009-01-08 Univ Of Tsukuba 蛋白質を含む液状組成物中における蛋白質の安定化方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19903693A1 (de) * 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
US7153679B2 (en) 2000-07-26 2006-12-26 Aventis Behring Gmbh Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
ES2257361T3 (es) 2000-07-26 2006-08-01 Zlb Behring Gmbh Mutantes de la proteasa activadora del factor vii y procedimiento de deteccion con anticuerpos especificos.
JP4005338B2 (ja) * 2000-11-29 2007-11-07 ペンタックス株式会社 抗体固相化担体、および、その製造方法
US20020114800A1 (en) 2000-11-29 2002-08-22 Asahi Kogaku Kogyo Kabushiki Kaisha Carrier having immobilized antigens or antibodies and method of manufacturing thereof
DE10148037A1 (de) * 2001-09-28 2003-04-17 Aventis Behring Gmbh Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen
DE10205520A1 (de) 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
AU2003232315A1 (en) * 2002-05-07 2003-11-11 Medical Research Council Sarcosyl buffer and its use for the purification of prion protein
KR100508606B1 (ko) * 2002-11-15 2005-08-17 주식회사 바이오세움 효소 안정화 조성물 및 상기 조성물을 이용한 효소 보관방법
RU2364626C2 (ru) * 2003-03-18 2009-08-20 Ново Нордиск Хелт Кэр Аг Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x
WO2008031020A2 (en) * 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
BRPI0810172A2 (pt) 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
EP2729570B1 (en) 2011-07-04 2017-11-22 Qiagen GmbH Reagent usable for the isolation and/or purification of nucleic acids
GB2504499A (en) * 2012-07-31 2014-02-05 Baxter Healthcare Sa Selective measurement of active human protease coagulation factors
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
DE19903693A1 (de) * 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6010015515, Ａｎｎ． Ｈｅｍａｔｏｌ． （Ｍａｒ １９９９受入れ） ｖｏｌ．７８， ｓｕｐｐｌ Ｉ， ｐ．Ａ１０（ＦＶ０２４） *
JPN6010015518, Ａｎｎ． Ｈｅｍａｔｏｌ． （Ｍａｒ １９９９受入れ） ｖｏｌ．７８， ｓｕｐｐｌ Ｉ， ｐ．Ａ４２（Ｐ０３０） *
JPN6010015520, 岡田雅人他編，無敵のバイオテクニカルシリーズ タンパク質実験ノート上抽出と分離精製，株式会社羊土社， *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009002709A (ja) * 2007-06-19 2009-01-08 Univ Of Tsukuba 蛋白質を含む液状組成物中における蛋白質の安定化方法

Also Published As

Publication number Publication date
ES2298110T3 (es) 2008-05-16
EP1074616B1 (de) 2008-02-20
US6677440B1 (en) 2004-01-13
ATE386798T1 (de) 2008-03-15
CA2315306A1 (en) 2001-02-06
DE19937219A1 (de) 2001-02-08
DE50014975D1 (de) 2008-04-03
EP1074616A1 (de) 2001-02-07
KR20010049988A (ko) 2001-06-15
US20040186277A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
JP2001086984A (ja) アフィニティークロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法
JP2001095563A (ja) イオン交換クロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法
NL8003402A (nl) Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
CA2640010A1 (en) Purification and use of a factor for supporting wound healing
US20140206844A1 (en) Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
Reber et al. Three abnormal fibrinogen variants with the same amino acid substitution (γ 275 Arg→ His): Fibrinogens Bergamo II, Essen and Perugia
JP4250769B2 (ja) 高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法
US5777081A (en) Process for producing an inter-alpha-trypsin inhibitor concentrate for therapeutic use and concentrate thus obtained
EP2640413B1 (en) A process for reduction and/or removal of fxi and fxia from solutions containing said coagulation factors
DK173151B1 (da) Fremgangsmåde til oprensning af enkeltkædet og dobbeltkædet vævsplasminogenaktivator
JPH0676438B2 (ja) 血液から単離された蛋白質、該蛋白質の製造方法および該蛋白質を含有する製薬学的組成物
EP0218479B1 (en) Process for the production of a plant protein reagent, binding to tPA
EP0139447B1 (en) A process for preparing urokinase zymogen
EP3512940B1 (en) Process for plasminogen purification starting from human plasma
Dempfle et al. Purification of human plasma fibrinogen by chromatography on protamine-agarose
JP7230115B2 (ja) 翻訳後修飾α－トロンビン
AU781717B2 (en) Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
RU2488403C1 (ru) Способ получения особо чистого препарата ферроксидазы церулоплазмина и/или фактора свертывания крови протромбина. аффинный неомициновый сорбент для их получения
CA3036425C (en) Process for plasminogen purification starting from human plasma
Frost et al. Purification and partial characterization of an ostrich α1-antichymotrypsin-like serum inhibitor
JPH0393798A (ja) プラスミノゲン活性化因子阻害剤２（ｐａｉ―２）の精製方法
Kim Purification, modification, characterization and crystallization of wild-type and recombinant forms of the corn inhibitor of activated Hageman factor
MANAHAN et al. A. 2. Structure and Function of Human Proteinase Inhibitors
JPH01148185A (ja) 逆相液体クロマトグラフィーによるｔ−ＰＡ精製方法
KR20020081601A (ko) Ｆａｃｔｏｒ Ｘａ 억제 단백질 및 그의 제조방법

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100914